Alembic Pharma's Q2 financials show mixed performance, with positive and negative aspects

Alembic Pharmaceuticals, a largecap company in the pharmaceuticals and drugs industry, has recently declared its financial results for the quarter ending September 2024. According to the latest report, the company has seen a flat performance in the second quarter of the fiscal year 2024-2025. This is reflected in the score, which has fallen from 8 to 3 in the last three months.

Despite this, there are some positive aspects to Alembic Pharma's financials. The company has shown a strong operating cash flow, with the highest annual amount of Rs 803.20 crore and a consistent growth over the past three years. Additionally, the net sales for the quarter have also been the highest in the last five quarters, at Rs 1,647.98 crore, indicating a positive trend in the near term.

The profit before tax less other income (PBT) for the quarter has also shown a growth of 21.14% year on year, standing at Rs 150.81 crore. This is another positive aspect for the company, with a positive trend in the near term.

However, there are also some areas that need improvement for Alembic Pharma. The debtors turnover ratio for the half yearly period is at its lowest in the last five periods, indicating a slower pace in settling debts. Additionally, the non-operating income for the quarter has been the highest in the last five quarters, which may not be sustainable in the long run.

Overall, Alembic Pharmaceuticals has shown a mixed performance in the recent quarter, with some positive and negative aspects. MarketsMOJO has given a 'Hold' call for the company's stock, indicating a neutral stance. Investors should carefully consider these financials before making any decisions regarding Alembic Pharma's stock.